Colorectal Cancer (CRC) Active Not Recruiting Phase 1 Trials for Carboplatin (DB00958)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Active Not Recruiting	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT06607185	A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors	Treatment	Carboplatin (DB00958) Cetuximab (DB00002) Cisplatin (DB00515) Fluorouracil (DB00544) Gemcitabine (DB00441) Irinotecan (DB00762) LY4066434 (DB22727) Leucovorin (DB00650) Oxaliplatin (DB00526) Paclitaxel (DB01229) Pembrolizumab (DB09037) Pemetrexed (DB00642)
NCT05704985	Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors	Treatment	Capecitabine (DB01101) Carboplatin (DB00958) DK210 (DB24308) Fluorouracil (DB00544) Nivolumab (DB09035) Oxaliplatin (DB00526) Paclitaxel (DB01229) Pembrolizumab (DB09037)
NCT04644068	Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies	Treatment	Camizestrant (DB19218) Carboplatin (DB00958) Datopotamab deruxtecan (DB16410) Paclitaxel (DB01229) Saruparib (DB18982) Trastuzumab deruxtecan (DB14962)
NCT03872947	A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors	Treatment	Bevacizumab (DB00112) Carboplatin (DB00958) Cisplatin (DB00515) Fluorouracil (DB00544) Gemcitabine (DB00441) Imiquimod (DB00724) Irinotecan (DB00762) Leucovorin (DB00650) Nivolumab (DB09035) Paclitaxel (DB01229) Pegylated doxorubicin (DB32018) Pembrolizumab (DB09037) Ramucirumab (DB05578) TRK-950 (DB22441)
NCT04083599	GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors	Treatment	Carboplatin (DB00958) Cisplatin (DB00515) Fluorouracil (DB00544) GEN1042 (DB22466) Gemcitabine (DB00441) Paclitaxel (DB01229) Pembrolizumab (DB09037) Pemetrexed (DB00642)